FDA sends interim peptide access policy to White House

Policy enters White House review

The submission moves the proposal forward within the executive branch, but it does not itself put the policy into effect.

The proposed policy would temporarily allow compounding pharmacies to produce and sell peptide products that had previously been restricted. It is structured as an interim access measure rather than a permanent authorization.

The proposal focuses specifically on access through compounding pharmacies. Its practical effect will depend on the final terms, including which peptide products are covered, when the temporary permission begins and how long it remains in place.

What happens next

White House review is the next step for the FDA proposal. The temporary access pathway cannot begin unless the review process is completed and the FDA takes the additional action needed to establish the policy.

The final policy text will be important for pharmacies, health care providers and patients seeking to understand its boundaries. Details to watch include any eligibility requirements, limits on production or sales, the effective date and the duration of the interim period.

The filing advances an executive-branch health policy decision; it does not create immediate access to the restricted peptide products. Until the policy is finalized and takes effect, compounding pharmacies cannot rely on the proposed temporary permission.